Salinomycin Selectively Targets ‘CD133+’ Cell Subpopulations and Decreases Malignant Traits in Colorectal Cancer Lines
- 788 Downloads
Cancer stem-like cells (CSCs) in colorectal cancers (CRC) may account for the failure of treatments because they are resistant to many current anticancer therapies. Salinomycin, a potassium ionophore, was recently identified as a selective inhibitor of breast CSCs.
The human CRC cell lines HT29 and SW480 were treated with salinomycin and oxaliplatin. Cell viability was determined with cell counting kit 8. Fraction of CD133+ cell subpopulations was assessed by Flow Cytometric analysis. Clonogenecity and migration were determined with soft agar and Boyden chamber assays. Molecular changes were assessed by immunofluorescence staining, RT-PCR, and Western blot analysis.
We report that salinomycin reduces the proportion of CD133+ subpopulations in human CRC HT29 and SW480 cells. Furthermore, salinomycin treatment decreases colony-forming ability and cell motility in HT29 cells. Moreover, salinomycin downregulates the expression of vimentin and induces the E-cadherin expression in HT29 cells.
This study demonstrates the ability of salinomycin to selectively target “CD133+” cell subpopulations and decrease the malignant traits in colorectal cancer lines.
KeywordsOxaliplatin Epithelial Mesenchymal Transition HT29 Cell SW480 Cell Salinomycin
This study was supported by the National Natural Science Foundation (No. 30901424) and the Leading Medical Talent Foundation of Shanghai Municipality (No. LJ06038). We thank the members of Bing-Ya Liu’s laboratory for helpful comments and discussions, Dr. Zhi-Qiang Chen for reagents, and Xiao-Shuang Yan for technical help.
This study was supported by the National Natural Science Foundation (No. 30901424) and the Leading Medical Talent Foundation of Shanghai Municipality (No. LJ06038). The authors declared no competing financial interests.
- 19.Ong CW, Kim LG, Kong HH, Low LY, Iacopetta B, Soong R, Salto-Tellez M. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol. 23(3):450–7.Google Scholar
- 21.Artells R, Moreno I, Diaz T, Martinez F, Gel B, Navarro A, Ibeas R, Moreno J, Monzo M. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients. Eur J Cancer. 2010;46(3):642–9.Google Scholar
- 27.Riccioni R, Dupuis ML, Bernabei M, Petrucci E, Pasquini L, Mariani G, Cianfriglia M, Testa U. The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis. 2010;45(1):86–92.Google Scholar
- 28.Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun. 2010;394(4):1098–104.Google Scholar
- 31.Li Y, Fang J, Wu S, Ma K, Li H, Yan X, Dong F. Identification and quantification of salinomycin in intoxicated human plasma by liquid chromatography-electrospray tandem mass spectrometry. Anal Bioanal Chem. 2010;398(2):955–61.Google Scholar
- 33.Kojima M, Ishii G, Atsumi N, Nishizawa Y, Saito N, Ochiai A. CD133 expression in rectal cancer after preoperative chemoradiotherapy. Cancer Sci. 2010;101(4):906–12.Google Scholar
- 35.Weinberg RA. The rational treatment of cancer. In: Zayatz E, editor. The biology of cancer. New York: Garland Science; 2007. p. 787–94.Google Scholar